Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
International Journal of Cancer|April 4, 2017
The proprotein convertase furin in tumour progressionPatricia Jaaks, Michele Bernasconi
Medicinal Research Reviews|June 17, 2024
Targeted immunotherapy and nanomedicine for rhabdomyosarcoma: The way of the futureVictoria Judith Morel, Jochen Rössler, Michele Bernasconi
Journal of Materials Chemistry. B|April 9, 2020
Peptides for tumor-specific drug targeting: state of the art and beyondMaurizio Roveri, Michele Bernasconi, Jean-Christophe Leroux, et al.
Trends in Microbiology|October 7, 2008
Role of latent membrane protein 2 isoforms in Epstein-Barr virus latencyMarkus P Rechsteiner, Michele Bernasconi, Christoph Berger, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 29, 2002
A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivoKimmo Porkka, Pirjo Laakkonen, Jason A Hoffman, et al.
Plos One|May 11, 2010
Furin targeted drug delivery for treatment of rhabdomyosarcoma in a mouse modelKatarina Hajdin, Valentina D'Alessandro, Felix K Niggli, et al.
Cancer Cell|December 12, 2003
Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesisJohanna A Joyce, Pirjo Laakkonen, Michele Bernasconi, et al.
The Journal of General Virology|April 7, 2007
Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cellsMarkus P Rechsteiner, Christoph Berger, Matthias Weber, et al.
Pageof 5